Literature DB >> 28786419

Cardiovascular toxicities of systemic treatments of prostate cancer: oestrogen to the rescue?

Syed Imran A Shah1, Hannah C P Wilson2, Paul D Abel3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28786419     DOI： 10.1038/nrurol.2017.126

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  7 in total

Review 1.  Estrogen therapy and liver function--metabolic effects of oral and parenteral administration.

Authors:  B von Schoultz; K Carlström; L Collste; A Eriksson; P Henriksson; A Pousette; R Stege
Journal:  Prostate       Date:  1989       Impact factor: 4.104

2.  Transdermal estradiol therapy for advanced prostate cancer--forward to the past?

Authors:  J L Ockrim; E-N Lalani; M E Laniado; S St C Carter; P D Abel
Journal:  J Urol       Date:  2003-05       Impact factor: 7.450

3.  Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate.

Authors:  D P Byar
Journal:  Cancer       Date:  1973-11       Impact factor: 6.860

Review 4.  Cardiovascular toxicities of systemic treatments of prostate cancer.

Authors:  Antonello Veccia; Francesca Maines; Stefania Kinspergher; Enzo Galligioni; Orazio Caffo
Journal:  Nat Rev Urol       Date:  2017-01-24       Impact factor: 14.432

5.  Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.

Authors:  Ruth E Langley; Ian F Godsland; Howard Kynaston; Noel W Clarke; Stuart D Rosen; Rachel C Morgan; Philip Pollock; Roger Kockelbergh; El-Nasir Lalani; David Dearnaley; Mahesh Parmar; Paul D Abel
Journal:  BJU Int       Date:  2008-04-16       Impact factor: 5.588

6.  Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.

Authors:  Per Olov Hedlund; Jan-Erik Damber; Inger Hagerman; Svein Haukaas; Peter Henriksson; Peter Iversen; Robert Johansson; Peter Klarskov; Finn Lundbeck; Finn Rasmussen; Eberhard Varenhorst; Jouko Viitanen
Journal:  Scand J Urol Nephrol       Date:  2008

7.  Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).

Authors:  Ruth E Langley; Fay H Cafferty; Abdulla A Alhasso; Stuart D Rosen; Subramanian Kanaga Sundaram; Suzanne C Freeman; Philip Pollock; Rachel C Jinks; Ian F Godsland; Roger Kockelbergh; Noel W Clarke; Howard G Kynaston; Mahesh Kb Parmar; Paul D Abel
Journal:  Lancet Oncol       Date:  2013-03-04       Impact factor: 41.316
  7 in total
  1 in total

1.  Cardiovascular toxicities of systemic treatments of prostate cancer: is oestrogen to the rescue?

Authors:  Antonello Veccia; Francesca Maines; Orazio Caffo
Journal:  Nat Rev Urol       Date:  2017-08-08       Impact factor: 14.432
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.